Stock PEHA PT PHAPROS, TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Phapros, Tbk

Equities

PEHA

ID1000147507

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 18:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
498 IDR 0.00% Intraday chart for PT Phapros, Tbk +0.40% -22.19%
04-06 PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 PT Phapros, Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,360,400 903,000 1,423,800 928,200 575,400 537,600
Enterprise Value (EV) 1 3,082,348 1,812,324 2,286,442 1,710,711 1,271,196 1,274,339
P/E ratio 17.8 x 8.85 x 29.4 x 83.8 x 20.5 x 90.2 x
Yield 5.6% 7.91% 1.36% 0.71% 1.95% -
Capitalization / Revenue 2.31 x 0.82 x 1.45 x 0.88 x 0.49 x 0.53 x
EV / Revenue 3.01 x 1.64 x 2.33 x 1.63 x 1.09 x 1.26 x
EV / EBITDA 14.6 x 8.6 x 22.1 x 12.5 x 8.02 x 13.9 x
EV / FCF -12.5 x -16.4 x 16.6 x 17.3 x 11.9 x -26.4 x
FCF Yield -8.01% -6.08% 6.03% 5.77% 8.41% -3.78%
Price to Book 3.07 x 1.13 x 1.98 x 1.29 x 0.77 x 0.72 x
Nbr of stocks (in thousands) 840,000 840,000 840,000 840,000 840,000 840,000
Reference price 2 2,810 1,075 1,695 1,105 685.0 640.0
Announcement Date 19-02-20 20-03-31 21-05-06 22-04-29 23-03-29 24-04-06
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,022,970 1,105,420 980,557 1,051,444 1,168,474 1,014,130
EBITDA 1 211,624 210,740 103,311 137,392 158,576 91,959
EBIT 1 186,585 168,904 60,253 94,725 117,549 53,490
Operating Margin 18.24% 15.28% 6.14% 9.01% 10.06% 5.27%
Earnings before Tax (EBT) 1 177,570 129,657 64,083 12,892 41,502 7,662
Net income 1 132,307 102,034 48,488 11,071 28,070 5,959
Net margin 12.93% 9.23% 4.94% 1.05% 2.4% 0.59%
EPS 2 157.5 121.5 57.72 13.18 33.42 7.094
Free Cash Flow 1 -246,772 -110,257 137,769 98,758 106,960 -48,228
FCF margin -24.12% -9.97% 14.05% 9.39% 9.15% -4.76%
FCF Conversion (EBITDA) - - 133.35% 71.88% 67.45% -
FCF Conversion (Net income) - - 284.13% 892.05% 381.05% -
Dividend per Share 2 157.5 85.03 23.09 7.900 13.37 -
Announcement Date 19-02-20 20-03-31 21-05-06 22-04-29 23-03-29 24-04-06
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 721,948 909,324 862,642 782,511 695,796 736,739
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.411 x 4.315 x 8.35 x 5.695 x 4.388 x 8.012 x
Free Cash Flow 1 -246,772 -110,257 137,769 98,758 106,960 -48,228
ROE (net income / shareholders' equity) 17.9% 12.7% 6.23% 1.52% 3.62% 0.78%
ROA (Net income/ Total Assets) 7.66% 5.32% 1.88% 3.15% 4.03% 1.87%
Assets 1 1,727,151 1,916,375 2,583,401 351,056 696,298 318,391
Book Value Per Share 2 917.0 953.0 857.0 857.0 894.0 892.0
Cash Flow per Share 2 129.0 127.0 71.70 112.0 176.0 78.40
Capex 1 83,806 30,637 26,968 7,227 10,772 13,420
Capex / Sales 8.19% 2.77% 2.75% 0.69% 0.92% 1.32%
Announcement Date 19-02-20 20-03-31 21-05-06 22-04-29 23-03-29 24-04-06
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT PHAPROS, TBK Stock PT Phapros, Tbk
-22.19% 26.05M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PEHA Stock
  4. Financials PT Phapros, Tbk